DiscoveRx
From Wikipedia, the free encyclopedia
| DiscoveRx | |
|---|---|
 |
|
| Type | Private |
| Founded | 2000 |
| Location | Fremont, California |
| Key people | Pyare Khanna, Ph.D. (President and CEO) Richard Eglen, Ph.D. (CSO) |
| Industry | manufacturing |
| Products | biochemical and cell-based assays |
| Revenue | not available |
| Website | http://www.discoverx.com/ |
DiscoverRx develops, commercializes and manufactures reagents and assay kits for the drug discovery market. Their focus is on lucrative protein target classes, such as G-protein-coupled receptors and kinases.
The company is built around a proprietary technology called enzyme fragment complementation or EFC which forms the basis of the assays that they design and market. In EFC, two β-galactosidase fragments are employed which are themselves inactive. One fragment (EA) has an inactivating deletion while the second fragment (ED) has a complementing fragment; in solution where both EA and ED are present, the fragments combine and active β-gal tetramers form spontaneously.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
